GenoMed’s Treatment for Prion Disease Including “Mad Cow Disease” to be Tested
Contact:
David W. Moskowitz MD
CEO, GenoMed, Inc.
Tel. 314-983-9933
dwmoskowitz@genomed.com
St. Louis, MO.—December 1, 2004—GenoMed, Inc. (Pink Sheets: GMED), a Next Generation DM™ (Disease Management) company that uses genomics to improve clinical outcomes, announced today that it is collaborating with British and Japanese experts to test the Company’s patent-pending treatment for prion diseases, also known as transmissible spongiform encephalopathies (TSE). Bovine spongiform encephalopathy (BSE, or “mad cow disease”) is the best known disease in this group.
Dr. Nikolai G. Rainov, a neurosurgeon at the Walton Centre for Neurology and Neurosurgery NHS Trust and the University of Liverpool, will participate in testing GenoMed’s patent-pending approach in animal models. Dr. Katsumi Doh-ura’s research group at Tohoku University in Sendai, Japan will carry out all animal experiments. Dr. Doh-ura belongs to the same University as the group of Japanese physician-scientists who recently published a paper showing that an ACE inhibitor could slow the progression of Alzheimer’s disease. GenoMed applied for patent protection on this approach in August, 2001; the Company’s patent is pending in both Japan and the U.S.
Said Dr. David Moskowitz, GenoMed’s CEO, “Our collaboration with Dr Rainov, an expert in the delivery of therapeutic agents to the brain, and Dr Doh-ura, who is one of the leading world experts in research on prion disease, is extremely exciting. Currently, there is no treatment for this group of diseases, but every country’s meat supply is at risk, including the United States’. If a treatment for prion diseases were to emerge, it would not only put peoples’ minds at ease, but encourage a similar approach in other neurodegenerative diseases like Alzheimer’s and Parkinson’s.”
About GenoMed
GenoMed is leading the clinical revolution which medical genomics has already made possible. GenoMed is currently marketing its protocol for preventing kidney failure due to high blood pressure and diabetes, and delaying emphysema. GenoMed's clinical trials for neurodegenerative diseases including Alzheimer’s, Parkinson’s, and ALS (“Lou Gehrig’s disease”) are Internet-based. To enroll in one of GenoMed's free clinical trials, please email dwmoskowitz@genomed.com.
. |
